Kuva plans fully funded offer for Lisata Therapeutics

Kuva Labs said it plans to submit a new fully funded offer to Lisata Therapeutics’ board by Aug. 31, 2026. The move revives a previously terminated transaction and could reshape Lisata’s strategic options if the financing is in place.

Why it matters: - Kuva Labs is trying again to buy or combine with Lisata Therapeutics after an earlier deal fell apart. - A fully funded offer could give Lisata shareholders a clearer path to value, while also advancing a potential combination of the companies’ oncology technologies. - The proposal comes after Kuva argued that patient-stratification tools could improve outcomes for Certepetide.

What happened: - Kuva Labs said on Aug. 21, 2026, that it intends to submit a new fully funded offer to Lisata Therapeutics’ board no later than Aug. 31, 2026. - The company said it remains interested in a transaction consistent with Lisata’s announced strategic goals. - Kuva said its prior proposed transaction with Lisata was terminated after Kuva could not complete the financing needed to fund the deal and Lisata declined a request to extend the tender offer period. - Kuva said the extension request followed its discovery of information it believed was material, including clinical trial agreements, operational liabilities and data relevant to trial outcomes.

The details: - Kuva Labs described itself as a clinical-stage oncology company. - Kuva said it has validated the strategic and scientific rationale for combining Kuva and Lisata technologies. - The company said Lisata failed to achieve primary endpoints in Phase 2 trials, likely because patients were not stratified before entering the trials. - Kuva said its NanoMark technology can identify patients more likely to respond to Certepetide. - Kuva said that capability could unlock the "true latent value" of Certepetide. - Mark Land, Kuva Labs’ CEO, said a fully funded and timely offer is the best path to deliver value to Lisata shareholders and bring the technology to patients quickly. - Kuva said it will provide further updates as appropriate.

Between the lines: - Kuva is framing the next offer as both a financing fix and a scientific case for why a combined company could perform better than Lisata alone. - The emphasis on patient stratification suggests Kuva believes the earlier clinical misses were not necessarily a dead end for the asset. - The company is also signaling that any new bid will need to avoid the funding and disclosure issues that derailed the prior attempt.

What's next: - Kuva plans to deliver its formal offer to Lisata’s board on or before Aug. 31, 2026. - Any response from Lisata could determine whether the companies reopen negotiations or stay apart. - Kuva said it will issue more updates if warranted.

The bottom line: - Kuva is making another run at Lisata, this time promising full financing upfront and pitching a scientific rationale centered on patient selection.